Global Age-Related Macular Degeneration (AMD) Therapeutics Market Status, Trends and

February 2022 | 123 pages | ID: G48E105B94C1EN
BisReport Information Consulting CO., Ltd

Abstracts

In the past few years, the Age-Related Macular Degeneration (AMD) Therapeutics market
experienced a huge change under the influence of COVID-19, the global market size of Age-
Related Macular Degeneration (AMD) Therapeutics reached (2021 Market size XXXX)
million $ in 2021 from (2016 Market size XXXX) in 2016 with a CAGR of xxx from 2016-
2021 is. As of now, the global COVID-19 Coronavirus Cases have exceeded 200 million, and
the global epidemic has been basically under control, therefore, the World Bank has
estimated the global economic growth in 2021 and 2022. The World Bank predicts that the
global economic output is expected to expand 4 percent in 2021 while 3.8 percent in 2022.
According to our research on Age-Related Macular Degeneration (AMD) Therapeutics
market and global economic environment, we forecast that the global market size of Age-
Related Macular Degeneration (AMD) Therapeutics will reach (2026 Market size XXXX)
million $ in 2026 with a CAGR of % from 2021-2026.

Due to the COVID-19 pandemic, according to World Bank statistics, global GDP has shrunk
by about 3.5% in 2020. Entering 2021, Economic activity in many countries has started to
recover and partially adapted to pandemic restrictions. The research and development of
vaccines has made breakthrough progress, and many governments have also issued various
policies to stimulate economic recovery, particularly in the United States, is likely to provide
a strong boost to economic activity but prospects for sustainable growth vary widely
between countries and sectors. Although the global economy is recovering from the great
depression caused by COVID-19, it will remain below pre-pandemic trends for a prolonged
period. The pandemic has exacerbated the risks associated with the decade-long wave of
global debt accumulation. It is also likely to steepen the long-expected slowdown in
potential growth over the next decade.

The world has entered the COVID-19 epidemic recovery period. In this complex economic
environment, we published the Global Age-Related Macular Degeneration (AMD)
Therapeutics Market Status, Trends and COVID-19 Impact Report 2021, which provides a
comprehensive analysis of the global Age-Related Macular Degeneration (AMD)
Therapeutics market , This Report covers the manufacturer data, including: sales volume,
price, revenue, gross margin, business distribution etc., these data help the consumer know
about the competitors better. This report also covers all the regions and countries of the
world, which shows the regional development status, including market size, volume and
value, as well as price data. Besides, the report also covers segment data, including: type
wise, industry wise, channel wise etc. all the data period is from 2015-2021E, this report
also provide forecast data from 2021-2026.

Section 1: 100 USD——Market Overview

Section (2 3): 1200 USD——Manufacturer Detail
Amgen Inc.
Bausch Health Companies, Inc.
F. Hoffmann-La Roche Ltd.
Novartis AG
Regeneron Pharmaceuticals Inc.

Section 4: 900 USD——Region Segmentation
North America (United States, Canada, Mexico)
South America (Brazil, Argentina, Other)
Asia Pacific (China, Japan, India, Korea, Southeast Asia)
Europe (Germany, UK, France, Spain, Italy)
Middle East and Africa (Middle East, Africa)

Section (5 6 7): 700 USD——
Product Type Segmentation
Wet AMD
Dry AMD

Application Segmentation
Hospital
Clinic
Research Institute

Channel (Direct Sales, Distribution Channel) Segmentation

Section 8: 500 USD——Market Forecast (2021-2026)

Section 9: 600 USD——Downstream Customers

Section 10: 200 USD——Raw Material and Manufacturing Cost

Section 11: 500 USD——Conclusion

Section 12: Research Method and Data Source

Contents

SECTION 1 AGE-RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS MARKET OVERVIEW

1.1 Age-Related Macular Degeneration (AMD) Therapeutics Market Scope
1.2 COVID-19 Impact on Age-Related Macular Degeneration (AMD) Therapeutics Market
1.3 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Status and
Forecast Overview
  1.3.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Status 2016-
2021
  1.3.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast 2021-
2026

SECTION 2 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS MARKET

Manufacturer Share
2.1 Global Manufacturer Age-Related Macular Degeneration (AMD) Therapeutics Sales
Volume
2.2 Global Manufacturer Age-Related Macular Degeneration (AMD) Therapeutics Business
Revenue

SECTION 3 MANUFACTURER AGE-RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS BUSINESS

Introduction
3.1 Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Business
Introduction
  3.1.1 Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Sales Volume,
Price, Revenue and Gross margin 2016-2021
  3.1.2 Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Business
Distribution by Region
  3.1.3 Amgen Inc. Interview Record
  3.1.4 Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Business Profile
  3.1.5 Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product
Specification
3.2 Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics
Business Introduction
  3.2.1 Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD)
Therapeutics Sales Volume, Price, Revenue and Gross margin 2016-2021
  3.2.2 Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD)
Therapeutics Business Distribution by Region
  3.2.3 Interview Record
  3.2.4 Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD)
Therapeutics Business Overview
  3.2.5 Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD)
Therapeutics Product Specification
3.3 Manufacturer three Age-Related Macular Degeneration (AMD) Therapeutics Business
Introduction
  3.3.1 Manufacturer three Age-Related Macular Degeneration (AMD) Therapeutics Sales
Volume, Price, Revenue and Gross margin 2016-2021
  3.3.2 Manufacturer three Age-Related Macular Degeneration (AMD) Therapeutics Business
Distribution by Region
  3.3.3 Interview Record
  3.3.4 Manufacturer three Age-Related Macular Degeneration (AMD) Therapeutics Business
Overview
  3.3.5 Manufacturer three Age-Related Macular Degeneration (AMD) Therapeutics Product
Specification
…

SECTION 4 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS MARKET

Segmentation (By Region)
4.1 North America Country
  4.1.1 United States Age-Related Macular Degeneration (AMD) Therapeutics Market Size and
Price Analysis 2016-2021
  4.1.2 Canada Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Price
Analysis 2016-2021
  4.1.3 Mexico Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Price
Analysis 2016-2021
4.2 South America Country
  4.2.1 Brazil Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Price
Analysis 2016-2021
  4.2.2 Argentina Age-Related Macular Degeneration (AMD) Therapeutics Market Size and
Price Analysis 2016-2021
4.3 Asia Pacific
  4.3.1 China Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Price
Analysis 2016-2021
  4.3.2 Japan Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Price
Analysis 2016-2021
  4.3.3 India Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Price
Analysis 2016-2021
  4.3.4 Korea Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Price
Analysis 2016-2021
  4.3.5 Southeast Asia Age-Related Macular Degeneration (AMD) Therapeutics Market Size
and Price Analysis 2016-2021
4.4 Europe Country
  4.4.1 Germany Age-Related Macular Degeneration (AMD) Therapeutics Market Size and
Price Analysis 2016-2021
  4.4.2 UK Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Price
Analysis 2016-2021
  4.4.3 France Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Price
Analysis 2016-2021
  4.4.4 Spain Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Price
Analysis 2016-2021
  4.4.5 Italy Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Price
Analysis 2016-2021
4.5 Middle East and Africa
  4.5.1 Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Price
Analysis 2016-2021
  4.5.2 Middle East Age-Related Macular Degeneration (AMD) Therapeutics Market Size and
Price Analysis 2016-2021
4.6 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Segmentation
(By Region) Analysis 2016-2021
4.7 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Segmentation
(By Region) Analysis

SECTION 5 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS MARKET

Segmentation (by Product Type)
5.1 Product Introduction by Type
  5.1.1 Wet AMD Product Introduction
  5.1.2 Dry AMD Product Introduction
5.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Volume by Dry
AMD016-2021
5.3 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Dry
AMD016-2021
5.4 Different Age-Related Macular Degeneration (AMD) Therapeutics Product Type Price
2016-2021
5.5 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Segmentation
(By Type) Analysis

SECTION 6 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS MARKET

Segmentation (by Application)
6.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Volume by
Application 2016-2021
6.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by
Application 2016-2021
6.2 Age-Related Macular Degeneration (AMD) Therapeutics Price in Different Application
Field 2016-2021
6.3 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Segmentation
(By Application) Analysis

SECTION 7 GLOBAL AGE-RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS MARKET